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Abstract:  
Influenza virus A (IVA) infection is responsible for recent death worldwide. Hence, there is a need to develop therapeutic agents against the virus. We describe the 
prediction of short interfering RNA (siRNA) as potential therapeutic molecules for the HA (Haemagglutinin) and NA (Neuraminidase) genes. We screened 90,522 
siRNA candidates for HA and 13,576 for NA and selected 1006 and 1307 candidates for HA and NA, respectively based on the proportion of viral sequences that 
are targeted by the corresponding siRNA, with complete matches. Further short listing to select siRNA with no off-target hits, fulfilling all the guidelines 
mentioned in approach, provided us 13 siRNAs for haemagglutinin and 13 siRNAs for neuraminidase. The approach of finding siRNA using multiple sequence 
alignments of amino acid sequences has led to the identification of five conserved amino acid sequences, three in hemagglutinin i.e. RGLFGAIAGFIE, 
YNAELLV and AIAGFIE and two in neuraminidase i.e. RTQSEC and EECSYP which on reveres translation provided siRNA sequences as potential therapeutic 
candidates. The approaches used during this study have enabled us to identify potentially therapeutic siRNAs against divergent IVA strains.  
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Background: 
Influenza viruses, a cause of significant morbidity and mortality in human 
population, possess a segmented genome of negative sense RNA encapsulated 
by a virally specified nucleoprotein. There are three types of influenza viruses 
that cause illness in humans: type A, B and C, classified according to the 
serological reactivity of internal proteins. The most common infectious agent 
of upper respiratory tract, Influenza A virus (IVA) is able to persistently re-
infect human populations by continually evading host immunity through the 
rapid evolution of surface antigens i.e. antigenic drift [1, 2, 3]. Influenza A 
virus can be further sub-typed according to the serological reactivity of its 
surface antigens (attachment protein of virus), HA (Haemagglutinin) and NA 
(Neuraminidase), proteins that are encoded on separate genome segments. To 
date, 15 HA subtypes and nine NA subtypes have been identified [4, 5]. IVA 
evolves rapidly because of the low fidelity of the RNA-dependent RNA 
polymerase. RNA-dependent RNA polymerases generally produce replication 
errors in 1/104 bases per replication cycle, whereas DNA polymerases produce 
replication errors in 1/109 bases per replication cycle. Due to this phenomenon 
individual point mutations lead to amino acid substitutions in the entire 
influenza genome, and particularly the ones that occur in the surface 
glycoproteins enabling influenza viruses to evade the host immune system and 
cause infection and re-infection despite the presence of pre-existing antibody 
due to ‘antigenic drift’ [3]. Every new antigenic drift variant of influenza A 
appears to have at least four amino acid substitutions located in two or more 
antigenic sites of the HA protein [3]. Furthermore, the segmented nature of the 
influenza genome facilitates the exchange of genetic information between 
different influenza viruses. This allows the virus to undergo drastic 
evolutionary changes resulting in ‘antigenic shift’ and hence emergence of 
antigenically novel influenza viruses. The presence of a large reservoir of 
influenza A viruses in birds increases the number of viral subtypes available for 
reassortment, when two different viruses from two different host species co-
infect a single individual animal, that have the potential to cause major global 
pandemics [3]. Due to such processes, human influenza is considered by some 
as a non eradicable disease, since the range of antigenically diverse subtypes of 
influenza A viruses are present in waterfowl and can be introduced into humans 
and may lead to millions of deaths [6-9]. Existing drugs and vaccines against 
Influenza A virus have limited value and the threat of pandemic persists. Broad 
spectrum anti-virals have been developed in the past that target an enzyme 
found in all viruses that have RNA genomes (except retroviruses) i.e. viral 
RNA-dependent RNA polymerases [10, 11].  
 
Apart from viral proteases and polymerases, some other viral proteins can act 
as potential drug targets. For instance, Inhibitors of virus entry is another new 
promising class of drugs that show clinical efficacy. In this regard, inhibitors 
that block virus entry into cells, by targeting the virus envelope glycoproteins 
have yielded a clinically approved compound for HIV [12]  as well as a 
promising lead to treat respiratory syncytial virus infections [13]. Similarly, 
inhibitors of the neuraminidase (glycoprotein) of influenza A and B viruses, 
two of which are zanamivir [14] and oseltamivir [15], are now approved for 
therapeutic use in humans. By inhibiting specific cell proteins that are required 
for virus replication it should be possible to interrupt the virus life cycle [16]. 
However, possible cross reactivity with host proteins can cause adverse side-
effects inhibiting essential host cell functions [17].  On contrary to agents 
typically inhibiting the function of crucial viral proteins, RNAi is the relatively 
newly described natural biological phenomenon that achieves the identical goal 
by targeting the viral mRNA instead of the proteins they encode. RNA 
interference (RNAi) is now being widely used to knockdown gene expression, BIOINFORMATION  open access 
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in a sequence specific manner, for therapeutic purposes [18, 19]. The efforts to 
develop anti-therapeutic agents directly from viral genome sequences has led to 
short (21-26 nucleotides) interfering RNA (siRNA), double-stranded RNA 
duplexes that mediate sequence-selective inhibition. In this regard, many 
experiments have been carried out in the past to clarify possible sequence 
requirements of functional siRNAs [19, 20]. The guidelines explained in three 
major previous studies [18-20] for selecting functional siRNAs are useful in 
selecting siRNA molecules for therapeutic purpose. However, designing 
functional siRNAs that target viral sequences is problematic because of their 
extraordinarily high genetic diversity. This problem suggests a strong need to 
select highly conserved target sites for designing siRNAs from the pool of 
various epidemic strains reported to date. Several types of modifications have 
been incorporated into the ends of the siRNA duplex to study their influence on 
the silencing ability and duration of their effect in the past [21]. Special care is 
suggested while designing siRNA as mismatches particularly in the centre of 
the siRNA duplex prevents target RNA cleavage [22]. The HA and NA have a 
central role in adaptation of virus, because of their interaction with host cell 
surfaces and proteases. In this study, we used web-based bioinformatics 
approach to predict siRNA neutralizing wider range of influenza virus A (IVA) 
variants by analyzing haemagglutinin (HA) and neuraminidase (NA) genes A 
(IVA). Moreover, reverse translational approach, using highly conserved amino 
acid sequences, was used to identify potentially important antiviral siRNAs. 
 
 
Figure 1: siRNA results for Haemagglutinins (A = siRNA sequence; B = 
siRNA position; C = siRNA efficacy predictions; D = Off-target search results. 
The number of human off-targets within two mismatches; E = Degrees of 
conservation; F = Conservation in the user-selected sequences) 
 
 
Figure 2: Graph showing percentage probability of predicted siRNA for 
Haemagglutinins. White Box represents the small fractions of siRNA filtered 
through all possible approaches (6.65%) 
 
Methodology: 
Selection & retrieval of sequences: 
To design siRNA, all the sequences of HA (segment 4) & NA (segment 6) 
genes of Influenza Virus A already present in the database 
[http://siVirus.rnai.jp] were initially selected, and then those sequences were 
short listed which were derived from viral isolates of a specific geographic 
region of Asia i.e. Hong Kong, China, Japan and Russia, for this study. 
Sequence data for gene segments 4 (Haemagglutinin) and 6 (Neuraminidase) of 
Influenza Virus A was collected for the past 39 years i.e. 1960-1999. The 
sequences from corresponding countries as mentioned above were downloaded, 
for multiple alignments, from NCBI Influenza Virus Sequence Database 
[http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html]. Sequences for siRNA 
were retrieved from siVirus based on their degree of conservation, defined as 
the proportion of viral sequences that are targeted by the corresponding siRNA, 
with complete matches (i.e. 21/21 matches). 
 
 
Figure 3: Result showing conserved regions in haemagglutinin using multiple 
sequence alignment 
 
siRNA analysis: 
siVirus  interface was used to determine anti-siRNA sequence results. This 
interface especially focuses on anti-siRNA design and provides (a) highly 
conserved target sites for designing anti-siRNA that would resist viral 
mutational escapes (b) selection of effective siRNAs based on guidelines of Ui-
Tei et al., Reynolds et al., Amarzguioui et al. [18-20] (c) Off-target minimized 
siRNAs within two mismatches against human genes. Off-target hits are those 
which have dissimilarity to the target sequence. It is desirable to select siRNA 
that has less off-target hits. 
 
Sequence analysis: 
TCOFFEE [http://www.ebi.ac.uk/t-coffee/.html] was used for multiple 
alignments to observe conservation and functional sites in the HA and NA 
datasets at amino acid level. The consensus in at least 7 amino acids 
corresponding to 21 nucleotides was noted. BLAST program was used for 
similar sequence searches. 
 
Results and Discussion: 
To design siRNA against influenza virus A, we analyzed all the sequences for 
gene segment 4 (haemagglutinin) and 6 (neuraminidase) of Influenza Virus A 
from some of the Asian countries (Tables 3 & 4 see Supplementary material) 
The selection of effective siRNAs sequences were based on published 
guidelines  [18-20]. Those guidelines were: (a) A/U at the 5’ end of the 
antisense strand, (b) G/C at the 5’ end of the sense strand, (c) At least 5 A/U 
residues at the 5’ terminal, one-third of the antisense strand (d) The absence of 
any GC stretch of more than 9 nucleotides in length. In case any of the above 
mentioned guideline is not fulfilled, then no gene silencing by a particular 
siRNA is expected. Furthermore, consensus in amino acid sequences in the HA 
(H1, H3, H5 and H9) and NA (N1-N2) of different strains was noted and only 
those strings of at least 7 amino acids were retained which were present in all 
types studied. 
 
siRNA prediction using siVirus: 
Figure 1 shows a typical output from siVirus for designing anti-influenza 
Virus A siRNAs. The sequences from Influenza virus A subtypes A and B, 
which are the most prevalent genotypes circulating in Asia, were selected. The 
results were sorted by the degree of conservation and filtered to display 
siRNAs that satisfy at least one efficacy guideline mentioned above. Out of 
90522 siRNA candidates screened, 1006 sequences targeting HA segment, 
whereas out of 13576 siRNA candidates screened, 1307 sequences targeting 
NA segment of influenza virus A genome were short listed respectively. 
Analysis of these siRNA candidates revealed that no conserved siRNAs were BIOINFORMATION  open access 
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obtained when using 90% conservation stringency parameter. However, on 
decreasing the stringency parameter close to 80%, 100% conservation of 
siRNAs pertaining to gene segment 4 (haemagglutinin) (Figure 1 & 2) and 
segment 6 (neuraminidase) (Data Not shown) was noted. Further short listing 
to select siRNA with no off-target hits, fulfilling all the guidelines mentioned 
in approach, provided us 13 siRNAs for haemagglutinin and 13 siRNAs for 
neuraminidase (Tables 1 & 2 see Supplementary material) 
 
siRNA prediction using conserved stretches of amino acids:  
Multiple sequence alignments of amino acids retrieved from NCBI 
[http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html]  (Tables 3 & 4, see 
supplementary material) resulted in obtaining some conserved strings of 
amino acids i.e., RGLFGAIAGFIE, YNAELLV and AIAGFIE in 
hemagglutinin (H) among different subtypes of segment 4 (H1, H2, H3, H5, 
H9)  (Figure 3) and RTQSEC and EECSYP in neuraminidase (N) among 
different subtypes of segment 6 (N1 and N2) for different Asian strains 
(Results not shown). Based on their degree of conservation, we suggest that 
these conserved amino acid segments could potentially act as useful targets for 
designing therapeutic siRNAs for different subtypes. These conserved amino 
acid sequences were reverse translated using a webserver 
[http://www.bioinformatics.org/sms2/rev_trans.html] and we obtained the RNA 
sequence “gcgauugcgggcuuuauugaa” for AIAGFIE, 
“cgcggcctguuuggcgcgauugcgggcuuuauugaa” for RGLFGAIAGFIE, 
“uauaacgcggaacugcuggug” for YNAELLV, “cgcacccaggaaagcgaaugc” for 
RTQESEC and “gaagaaugcagcugcuauccg” for EECSCYP. A number of studies 
demonstrated inhibition of replication of RNA viruses by RNAi [25, 26], 
including HIV, Polio virus, Hepatitis C virus, West Nile virus and Influenza 
virus [27, 28]. The approach of identifying siRNAs by reverse translation of the 
consensus motifs/conserved amino acid string from different subtypes of 
haemagglutinin and neuraminidase can be a useful strategy. This needs to be 
incorporated in any such software tool to obtain more effective translation 
inhibitor siRNA molecules covering broader range of influenza subtypes. The 
approach will also help designing antiviral siRNAs that would resist viral 
mutational escapes. 
 
Conclusion: 
To identify new potential leads for developing antiviral therapies against IVA 
we screened an siRNA library targeting haemagglutinin and neuraminidase. 
For this it was desirable to select an siRNA that had less off target hits and 
hence to be more specific. The current in silico study resulted in finding 
various targets for siRNA in haemagglutinin and neuraminidase and the results 
may have implications in developing prophylactic as well as therapeutic 
treatment against influenza infection. Another interesting finding of the current 
study was obtaining few but completely different siRNA targets in HA and NA 
genes compared to our conventional siRNA identification approach using web 
based tools, when we reverse translated conserved amino acids back to RNA. 
We believe that the approach of developing siRNA based on combination of 
both approaches i.e. Direct search for siRNA against appropriate targets and 
finding the consensus of amino acids of majority of the circulating virus 
variants would provide a broad range protection molecule to control the 
infection. 
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Supplementary material: 
 
Table 1: siRNA result for Haemagglutinin for Asia 
S#  SiRNA target sites + 2 Nucleotides overhang  % conservation 
1 CAGCAACTGTTACCCTTATGAtg  82.9  (834/1006) 
2 AAGCATCTATTGGACAATAGTaa  81.6  (821/1006) 
3  TACGGTTTCAGGCATCAAAATtc  81.2  (817/1006) 
4 ACGGTTTCAGGCATCAAAATTct  81.2(817/1006) 
5 ATGGAAGCATTCCCAATGACAaa  80.8  (813/1006) 
6 TGGAAGCATTCCCAATGACAAac  80.8  (813/1006) 
7 CAGCAACTGTTACCCTTATGAtg  72.2  (86/119) 
8 TACGGTTTCAGGCATCAAAATtc  72.2  (86/119) 
9 ACGGTTTCAGGCATCAAAATTct  72.2  (86/119) 
10 GGCAACATTAGGTGCAACATTtg  69.7  (83/119) 
11 AGGTGCAACATTTGCATTTGAgt  68  (81/119) 
12 ATGGAAGCATTCCCAATGACAaa  67.2  (80/119) 
13 TGGAAGCATTCCCAATGACAAac  67.2  (80/119) 
 
Table 2: siRNA result for Neuraminidase for Asia 
S#  SiRNA target sites + 2 Nucleotides overhang  % conservation 
1 TAGCATGGTCCAGCTCAAGTTgt  85  (1112/1307) 
2 CTCAAGTTGTCACGATGGAAAag  84.1  (1100/1307) 
3 TGCAACTGCTAGCTTCATTTAtg  83.3  (1090/1307) 
4 ATGCAACTGCTAGCTTCATTTat  83.3  (1089/1307) 
5 GTGCTTTTATGTGGAGTTGATaa  82  (1073/1307) 
6 ATCCAAATCAAAAGATAATAAca  81.4  (1064/1307) 
7 ATGAATCCAAATCAAAAGATAat  74  (120/162) 
8 ATCCAAATCAAAAGATAATAAca  74  (120/162) 
9 TAGCATGGTCCAGCTCAAGTTgt  72.8  (118/162) 
10 CTCAAGTTGTCACGATGGAAAag  72.2  (117/162) 
11 TGCAACTGCTAGCTTCATTTAtg  71.6  (116/162) 
12 ATGCAACTGCTAGCTTCATTTat  70.9  (115/162) 
13 TTGCACCTTTTTCTAAGGACAat  70.3  (114/162) 
 
 Table 3: Haemagglutinin sequences used for BLAST and multiple sequence alignment. 
S#  Influenza A   Accession Number  Country of Origin 
1 H1  33622380  Beijing 
2 H1  33622384  Shenzhen 
3 H1  221340  A/Suita/  Japan 
4 H1  554652  USSR 
5 H2  305115  Japan 
6 H2  408525  Krasnodar 
7 H3  49339089  Hong  kong 
8 H3  77861715  Hong  Kong 
9 H3  18615859  Udorn 
10 H3  71558927  Moscow 
11 H5  71013498  Hong  Kong 
12 H5  2865380  Hong  Kong 
13 H5  2833657  Hong  Kong 
14 H5  3421252  Hong  Kong 
15 H9  8894694  Hong  Kong 
 
Table 4: Neuraminidase sequences used for BLAST and multiple sequence alignment. 
S#  Influenza A   Accession Number  Country of Origin 
1 N1  31096405  China 
2 N1  31096413  Hong  Kong 
3 N1  31096415  Hong  Kong 
4 N1  2833659  Hong  Kong 
5 N1  3335423  Hong  Kong 
6 N1  47834892  Hong  Kong 
7 N1  47834894  Hong  Kong 
8 N1  324578  Russia 
9 N2  38524538  Japan 
10 N2  49473497  Japan 
11 N2  418078  China 
12 N2  8894698  Hong  Kong 
13 N2  21632606  China 
14 N2  21632610  China 
15 N2  81174818  Hong  Kong 
16 N2  8250669  Russia 
17 N2  71553740  Russia 
 